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Sir2 is a NAD+-dependent deacetylase, which regulates life 
span in multiple model organisms in response to caloric restric-
tion. Mammalian homologues of Sir2 comprise a family of seven 
proteins termed sirtuins (SIRT1-SIRT7), which have gained 
considerable attention for their impact on several important physi-
ological processes associated with metabolism and stress resistance. 
In addition, recent studies point to SIRT1 as a key regulator of 
vascular endothelial homeostasis controlling angiogenesis, vascular 
tone and endothelial dysfunction. Here, we review the emerging 
role of SIRT1 as an important modulator of signaling networks 
critical for maintaining vascular endothelial homeostasis and 
discuss SIRT1 as a potential therapeutic target for cardiovascular 
diseases in the adult.
Histone Deacetylases and Vascular Endothelial Homeostasis
Blood vessels form a highly organized and stereotyped vascular 
network, which is essential for the delivery of nutrients, gases, macro-
molecules and cells to all organs in the body. The formation and 
growth of blood vessels plays a fundamental role for organ growth 
and regeneration and the vascular network needs to expand signifi-
cantly during both, embryonic and postnatal development.1-3 When 
blood vessel growth is dysregulated, it is a key contributing factor 
for numerous malignant, ischemic and inflammatory diseases.1-3 
Endothelial cells line the inner surface of the vasculature and are 
essentially required for angiogenic blood vessel growth, which is the 
formation of new vessels from pre-existing ones by means of endo-
thelial sprouting, migration and proliferation.1-3 In addition to their 
role in angiogenesis, endothelial cells control vascular tone, blood 
coagulation, and are important mediators of inflammation.4 Precise 
control of endothelial cell functions is, thus, critical for the mainte-
nance of blood vessel homeostasis.
The transcriptional regulation of vascular homeostasis requires the 
coordinated action of several transcription factors and their associa-
tion with cofactors (coactivators amd corepressors), which allow for a 
precise time- and signal-dependent regulation of gene expression.5-7 
Histone deacetylases (HDACs) act as critical transcriptional cofactors 
that are recruited to promoters by sequence-specific transcription 
factors to regulate gene expression. By removing acetyl groups from 
nucleosomal histones, HDACs counteract the stimulatory effects of 
histone acetyltransferases (HATs) resulting in chromatin condensa-
tion with consequent transcriptional repression.8,9 In addition to 
chromatin remodeling, reversible acetylation has emerged as an 
important post-translational modification of several non-histone 
proteins, which are targeted and regulated by HDACs.10
HDACs can be classified into three classes based on their 
sequence homology with yeast proteins Rpd3 (class I), Hda1 (class 
II) and Sir2 (class III).11 Class I and II HDACs have been shown 
to play important roles in vascular biology by controlling endothe-
lial gene expression and vascular development.12-15 Amongst these 
enzymes, particularly class II HDACs appear to have a key function 
for the maintenance of vascular endothelial homeostasis.12,16 For 
example, deletion of the HDAC7 gene, which is expressed specifi-
cally in endothelial cells during embryonic development, resulted in 
embryonic lethality due to the loss of vascular integrity in mice.12 
In contrast, the role of members of the structurally and functionally 
distinct class III enzymes (sirtuins) in vascular endothelial homeo-
stasis remains poorly defined.
The Sirtuin Gene Family
The evolutionary conserved silent information regulator (Sir2) 
protein is the founding member of class III enzymes, which 
controls longevity in response to caloric restriction in many organ-
isms, including yeast, worms, flies and possibly mammals.17-21 In 
mammals there are 7 homologues of Sir2 termed sirtuins (SIRT1–
SIRT7) among which SIRT1 is the closest human homologue of 
yeast Sir2.22 Each sirtuin familiy member is characterized by a highly 
conserved, NAD+-dependent catalytic core domain (sirtuin domain), 
first identified in the yeast Sir2 protein.22 Mammalian sirtuins have 
diverse cellular localizations, modify multiple substrates, and affect 
numerous cellular functions. Amongst these, SIRT1, SIRT6 and 
SIRT7 are classified as the nuclear sirtuins, although SIRT1 is not 
restricted to the nucleus and appears to have important non-nuclear 
functions.23 SIRT3, SIRT4 and SIRT5 reside in the mitochondria, 
whereas SIRT2 is localized predominantly in the cytoplasm.23 
Sirtuins differ not only in their sub-cellular localization, but also 
in their enzymatic activity. SIRT1, SIRT2, SIRT3 and SIRT5 
are NAD-dependent deacetylases, whereas SIRT4 and SIRT6 are 
primarily mono-ADP-ribosyl transferases with no apparent deacety-
lase activity on histone substrates in vitro.23 The enzymatic activity 
of SIRT7 remains to be determined.
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Sirtuin Functions in Physiology and Disease
While it is not clear whether sirtuins regulate lifespan in 
mammals, systematic analysis of sirtuin knockout mice has revealed 
that this group of proteins serves essential functions during embry-
onic and postnatal development. Amongst the published sirtuin 
knockout mice, SIRT1- and SIRT6-deficient mice display the most 
severe phenotypes and are characterized by complex developmental 
defects.24-26
SIRT1 knockout mice are early postnatal lethal and exhibit heart 
and retinal developmental defects.24,25 In addition to the essential 
functions of SIRT1 during embryonic and early postnatal develop-
ment, SIRT1 maintains its important regulatory role for several 
homeostatic programs during adulthood. Indeed, SIRT1 has been 
shown to be a key component in several stress-responsive pathways 
involved in apoptotic cell death and cellular senescence and to 
control metabolic processes such as fat and glucose homeostasis.23,27 
The physiologic effects of SIRT1 are mediated by targeting a large 
number of substrates for deacetylation, including p53, Foxo, PPARγ 
cofactors NCoR/SMRT, PGC1α or LXR proteins.28-34 SIRT3-
deficient mice, which do not have an obvious phenotype under basal 
conditions, are characterized by hyperacetylation of mitochondrial 
proteins suggesting that its main function is to control the acetyla-
tion levels of mitochondrial proteins.35 Analysis of SIRT4 null mice 
revealed a role of SIRT4 in pancreatic beta cell mitochondria, in 
which SIRT4 inhibits insulin secretion in response to amino acids, 
thereby, opposing the effects of caloric restriction in these cells.36 
Although born at Mendelian ratios, SIRT6 deficiency is associated 
with a severe degenerative syndrome phenotype resembling some 
aspects of premature ageing leading to death at about 4 weeks of 
age.26 Mechanistically, SIRT6 promotes resistance to DNA damage 
and suppresses genomic instability in association with a role in 
base excision repair (BER). Consequently, loss of SIRT6 leads to 
increased genomic instability associated with impaired cellular 
growth and increased sensitivity to genotoxic stresses.26 Recently, 
SIRT7-deficient mice have been shown to undergo a reduction in 
mean and maximum lifespans and to develop heart hypertrophy and 
inflammatory cardiomyopathy suggesting roles for this particular 
sirtuin in stress resistance and apoptosis in cardiomyocytes.37
Requirement of Endothelial SIRT1 for Postnatal Vascular 
Growth
In an effort to identify the functions of sirtuins in vascular endo-
thelial cells, SIRT1 was recently identified as a critical regulator of 
sprouting angiogenesis during vascular growth.38 Using a three-
dimensional assay of sprouting angiogenesis assay combined with 
RNA interference to specifically knock down individual SIRT family 
members as a model system, SIRT1 deacetylase activity was shown 
to be critical for the angiogenic activity of endothelial cells. Although 
endothelial cells expressed all sirtuin family members, knock down 
of SIRT1 was uniquely associated with a near total loss of sprouting 
angiogenesis in vitro.38
The most remarkable function of SIRT1 in the endothelium was 
revealed by an aberrant neovascularization response of endothelial-
restricted SIRT1 mutant mice, in which the deacetylase domain 
was removed by Cre-mediated excision. Although genetic deletion 
of SIRT1 activity in the endothelium failed to induce an overt 
phenotype during embryonic development, analysis of postnatal 
neovascularization demonstrated that these SIRT1 mutant mice were 
characterized by an impaired ability to form new vessels in response 
to angiogenic signals such as ischemic stress.38 Obviously, the lack of 
an overt phenotype during embryonic vascular development raises 
the question whether redundancy among the different sirtuins might 
compensate for each other’s loss in vivo. While this issue needs to 
be addressed in future studies, these findings also suggest that the 
signaling pathways, which transduce postnatal angiogenic responses 
are not necessarily operational during embryonic development and 
imply that SIRT1 responds to specific signals postnatally to mediate 
its effects on vascular growth (e.g., upon ischemia). These results 
are consistent with a role of SIRT1 as a mediator of stress-induced 
signaling pathways as it has been shown for other cell types and 
tissues and identify SIRT1 as a signal-responsive regulator of vascular 
growth.
A clue to the mechanism of how SIRT1 modulates endothelial 
angiogenic functions came from the time-lapse analysis of segmental 
vessel formation in transgenic zebrafish embryos with fluorescently 
labeled endothelial cells in which segmental arteries emanate from 
the dorsal aorta to form the dorsal longitudinal anastomosing vessel. 
Compared to the highly organized process of blood vessel formation 
in the control embryos, SIRT1-deficient zebrafish were characterized 
by vascular patterning defects and hemorrhages due to dysregulated 
endothelial sprouting and vessel navigation.38 Consistent with 
these observations, loss of SIRT1 activity by either pharmacological 
inhibition, RNAi-mediated gene silencing or Cre-mediated exci-
sion of the floxed SIRT1 deacetylase domain blocked the ability 
of endothelial cells to form vascular-like sprouts and networks 
in vitro.38 Importantly, the reduced angiogenic activity was not 
a reflection of an overall reduced biological activity as apoptotic 
cell death or cell cycle arrest were not significantly altered in these 
cells under basal conditions. Taken together, these findings iden-
tify the NAD-dependent deacetylase SIRT1 as critical regulator of 
endothelial angiogenic functions and postnatal vascular growth. 
Although the usefulness of SIRT1 as a pharmacological target needs 
to be addressed in additional ischemia and tumor models, one may 
speculate that modulation of SIRT1 activity might provide novel 
opportunities to modulate angiogenesis and blood vessel homeostasis 
for regeneration and cancer treatment.
Role of SIRT1 in Vascular Tone and Stress-Induced 
Endothelial Dysfunction
In addition to its function as a regulator of angiogenesis, sirtuins 
may play a critical role in endothelial homeostasis by regulating the 
endothelial nitric oxide synthase (eNOS). Endothelial-derived nitric 
oxide (NO) regulates blood vessel relaxation and provides atheropro-
tective effects. Resveratrol, a polyphenolic activator of SIRT1, has 
been shown to increase the expression of eNOS39 and the combina-
tion of resveratrol with the HMG-CoA reductase inhibitors (statins) 
increased the activation of eNOS resulting in increased functional 
recovery in a model of acute myocardial infarction.40 Additionally, 
chronic resveratrol treatment improved endothelium-dependent 
relaxation in spontaneous hypertensive rats, however, it did not 
increase eNOS expression.41 A recent study by Mattagajashingh 
and colleagues might explain the mechanism underlying the post-
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shown to promote endothelial-dependent vasodilation by targeting 
endothelial nitric oxide synthase (eNOS) for deacetylation leading 
to enhanced nitric oxide production.42 Likewise, blocking SIRT1 
function by transduction of endothelial cells with a deacetylase-
defective SIRT1 mutant decreased NO-bioavailability and inhibited 
endothelium-dependent vasorelaxation. Interestingly, caloric restric-
tion, which is known lo lower blood pressure, led to the deacetylation 
of eNOS suggesting that the caloric restriction-induced decrease in 
blood pressure might result from a SIRT1-dependent deacetylation of 
eNOS.42 Consistent with an important role of SIRT1 in maintaining 
endothelial function, a recent report demonstrated that blocking 
SIRT1 by either pharmacological inhibition or RNAi-mediated 
knock down induced premature senescence-like phenotypes in 
endothelial cells.43 Conversely, overexpression of SIRT1 prevented 
hydrogen peroxide-induced endothelial senescence suggesting that 
activating SIRT1 might exert protective effects on the vascular 
endothelium by preventing stress-induced endothelial dysfunction, 
an early step in the pathogenesis of several cardiovascular diseases.43
In addition to its cell-autonomous role in the vascular endothelial 
homeostasis, SIRT1 might also modulate vascular homeostasis by 
beneficially affecting several metabolic pathways involved in cardio-
vascular disease progression such as cholesterol metabolism, glucose 
homeostasis and insulin resistance.27 Recent reports have shown that 
SIRT1 deacetylates and thereby activates the nuclear receptor LXR, 
a central transcriptional regulator of reverse cholesterol transport.34 
By modulating the activity of this nuclear factor, SIRT1 might favor 
cholesterol removal from peripheral tissues and, thus, prevent the 
formation of age-associated atherosclerotic lesion formation.34,44
SIRT1 has also been shown to improve insulin resistance,45,46 
a key contributing factor for the development of type 2 diabetes. 
Whereas loss of SIRT1 activity induces insulin resistance, over-
expression of SIRT1 or enhancing its activity by treatment with 
resveratrol improved insulin sensitivity especially under insulin-
resistant conditions.45,46 Taken together, these findings advance 
the knowledge of SIRT1 as a key regulator of tissue homeostasis by 
defining the vascular endothelium as an important target tissue for 
the direct and indirect actions of SIRT1.
Molecular Targets of SIRT1 in Endothelial Cells
Besides histones, several non-histone proteins are targeted by 
SIRT1 for deacetylation. Among these are several transcription 
factors, transcriptional cofactors and chromatin modifying enzymes, 
including p53, Foxo, NCoR/SMRT, PGC1α or SUV39H1, which 
mediate specific SIRT1-dependent cellular responses.28-33,47
Several studies highlight the importance of SIRT1 in mediating 
stress resistance by interfering with stress-responsive pathways 
(e.g., p53, Foxo or NBS1).28-31,48-50 For example, SIRT1 has 
been shown to promote cell survival in response to cellular stress 
by deacetylating the tumor suppressor protein p53, which down-
regulates p53 stability and activity.24,28,29,51 In addition, SIRT1 
associates with forkhead transcription factors (Foxo) upon exposure 
to hydrogen peroxide (H2O2) to mediate Foxo deacetylation and 
target gene expression.30,48,52 This stress-responsive and evolutionary 
highly conserved interaction of SIRT1 and Foxo transcription factors 
has been adopted by the vascular endothelium to control its angio-
genic activity. Indeed, Foxo family members have been identified 
as essential negative regulators of blood vessel formation among 
which Foxo1 appears to be the physiologically most important 
repressor of endothelial integrity.53,54 Using gain- and loss-of-func-
tion approaches, it has been demonstrated that SIRT1 has the ability 
to repress Foxo1-dependent transcriptional activity in endothelial 
cells38 and, thus, point to this transcription factor as an effector 
in the SIRT1-dependent angiogenic signaling pathway. However, 
the mode of Foxo regulation by SIRT1 remains controversial, with 
some data suggesting that deacetylation decreases31,38,55 and others 
that it increases Foxo activity.30,48,49,56 The molecular basis for these 
apparent differences is currently unclear. However, given the fact that 
Foxo1 is acetylated on several lysine residues,30,52,57 it is tempting to 
speculate that dependent on cofactor recruitment of Foxo1, SIRT1 
might only have access to a subset of acetylated lysine residues leading 
to a signal-dependent acetylation pattern of Foxo1, thereby, modu-
lating its biological activity. In addition, it is notable that acetylation 
of Foxo1 might compete with other posttranslational modifications 
such as ubiquitylation or sumoylation for the same lysine acceptor 
sites to regulate gene expression.58 The transcriptional output might, 
thus, depend on the combination of distinct posttranslational modi-
fications converging on Foxo lysine residues.
Although Foxo1 is an important deacetylation target of SIRT1 
in the vascular endothelium, the data available so far point to the 
existence of additional molecular targets of SIRT1, as neither the 
dysregulated gene expression nor the loss of angiogenic sprouting 
could be fully attributed to an inhibition of Foxo1.38 Given the 
multitude of SIRT1 interacting partners described in other cells 
and tissues,27 it is more than likely that SIRT1 has additional 
partners in vascular endothelial cells to mediate its specific effects. 
Intriguingly, SIRT1 has been shown to interact with eNOS,42 which 
plays a key role in maintaining vascular homeostais. SIRT1 has been 
shown to bind to eNOS and deacetylate lysines 496 and 506 in the 
calmodulin-binding domain of eNOS leading to enhanced NO 
production. 42 Given that eNOS-derived NO is not only essential for 
endothelial-dependent vasorelaxation,59 but also for endothelial cell 
survival, migration and postnatal neovascularization,60-64 NO might 
contribute to the Foxo-independent effects of the SIRT1-dependent 
regulation of sprouting angiogenesis. Of note, the Foxo transcrip-
tion factors Foxo1 and Foxo3a have been shown to repress eNOS 
expression53 suggesting a crosstalk between SIRT1, Foxos and eNOS. 
However, eNOS mRNA was not significantly downregulated in 
SIRT1-silenced endothelial cells38 implying that additional cofactors 
contribute to the Foxo-dependent regulation of eNOS expression.
In overexpression studies, Takata and colleagues reported that 
SIRT1 associated with the Hairy and Enhancer-of-split basic 
helix-loop-helix (bHLH) transcriptional repressor Hey2 to mediate 
transcriptional repression.65 Hey2 is the human homologue of the 
zebrafish gridlock, which has been shown to be an important regu-
lator of endothelial gene expression and mutant mice lacking Hey1 
and Hey2 are embryonically lethal due to defects in vascular devel-
opment.66 While it needs to be proven whether such an interaction 
occurs in endothelial cells, Hey2 appears to be an attractive target, 
given its essential functions in the cardiovascular system and recent 
reports demonstrating the importance of the Delta-like 4/Notch/
Hey signaling cascade for controlling tip cell formation and vascular 
patterning.67-71 Thus, it is indeed tempting to hypothesize that 
SIRT1 modulates endothelial angiogenic activity by interfering with 
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It is well conceivable that in addition to the targets outlined here 
in brief (Fig. 1), SIRT1 has additional binding partners in endothe-
lial cells and, thus, point to this deacetylase as a point of convergence 
of several signaling pathways critical for homeostatic endothelial 
functions. In the future, it will be interesting to identify these novel 
SIRT1-regulated factors and to investigate their involvement in 
vascular growth and disease.
Gene Targets of SIRT1 in Endothelial Cells
By associating with transcription factors and transcriptional cofac-
tors, SIRT1 acts as an important modulator of gene expression. In 
endothelial cells, gene targets (direct and indirect) of SIRT1 have 
been assessed by RNA interference-mediated knock down of SIRT1. 
This expression screen revealed that loss of SIRT1 activity leads to 
the dysregulation of several genes with essential roles in cardiovas-
cular development and homeostasis. Among the regulated genes 
were several transcription factors (e.g., Fli1, Hex), members of the 
TGFβ signaling cascade (e.g., SMAD7, Tak1), cell surface receptors 
(e.g., Flt1, CXCR4) and important signaling molecules involved in 
angiogenesis and vascular remodeling.38
Although the upstream mechanisms (direct and indirect) leading 
to the dysregulation of most of these genes remain to be determined, 
they provide interesting mechanistic insights of how SIRT1 might 
coordinate signaling networks and affects endothelial cell behavior. 
As such, the SIRT1 siRNA induced reduction of MMP14 (MT1-
MMP), a membrane-anchored matrix metalloproteinase essential for 
tip cell activity during sprouting angiogenesis,72,73 suggests that it 
might contribute to the path-finding defects observed in the SIRT1-
deficient zebrafish.38
In addition, the altered expression of genes involved in TGFβ 
signaling suggests that SIRT1 might be a key modulator of this 
signaling pathway by interfering with an upstream regulator or 
even an TGFβ transcriptional effector such as SMAD proteins.38 
Consistent with these considerations, SIRT1 has been reported to 
interact and deacetylate SMAD7, which is an auto-inhibitory down-
stream molecule of TGFβ signaling.74
A caveat to the identification of SIRT1-modulated genes is that 
SIRT1 appears to be a context/signal-dependent regulator of cellular 
responses. While the gene expression profile in SIRT1-deficient 
endothelial cells clearly support a role of SIRT1 in the transcrip-
tional control of endothelial homeostatic functions, it remains to 
be determined whether the gene expression changes observed in 
the microarray analysis performed under basal conditions reflect 
the entire signaling network of SIRT1 in vascular homeostasis. It is, 
thus, tempting to speculate that the gene targets of SIRT1 will most 
likely depend on the activity and acetylation pattern of the signaling 
pathway targeted by SIRT1.
SIRT1 as a “Drugable” Target for Cardiovascular Disease
The important role of SIRT1 for vascular endothelial homeostasis 
in vivo as well as its obvious beneficial effects on metabolic path-
ways, which critically contribute to the progression of cardiovascular 
disease, suggest opportunities for therapeutically exploiting the func-
tion of SIRT1 in the setting of cardiovascular diseases. Because SIRT1 
targets several proteins in distinct signaling pathways for deacetyla-
tion, modulation of SIRT1 activity could alter the biological activity 
of entire signaling networks and thereby modify complex disease 
processes such as pathological angiogenesis or atherosclerosis. Indeed, 
recent studies reported that resveratrol mimicked the anti-ageing 
effects of calorie restriction in mice fed a high-fat diet and amelio-
rated insulin resistance and prolonged survival.75,76 Although it is 
still not clear, whether resveratrol acts directly or indirectly through 
SIRT1 in vivo,77 the recently developed small molecule activators of 
SIRT1 that are structurally unrelated to, and 1.000-fold more potent 
than resveratrol, induce many of the beneficial metabolic changes 
observed after caloric restriction/resveratrol treatment, point to 
SIRT1 as a promising new therapeutic approach for treating diseases 
of ageing.46 Thus, the identification of an intrinsic function of 
SIRT1 in the endothelium suggests that diseases of the cardiovascular 
system might be particularly sensitive to SIRT1-modifiying drugs. 
Based on these considerations, one would predict that activation 
of SIRT1 would not only benefically affect established risk factors 
such type 2 diabetes or cholesterol homeostasis, but would also 
directly protect the endothelium by preventing endothelial dysfunc-
tion. Likewise, SIRT1 activation might ameloriate ischemic vascular 
diseases by promoting angiogenesis or by enhancing progenitor cell-
mediated neovascularization. As such, resveratrol was recently shown 
to increase the number of endothelial progenitor cells in vitro.78-80
The finding that SIRT1 acts as an important regulator of post-
natal vascular growth suggests that strategies to inhibit SIRT1 
activity could also provide an opportunity for anti-angiogenesis 
therapies. Dysregulation of angiogenic growth has been shown to 
contribute to numerous pathologies including malignant or inflam-
matory disorders and anti-angiogenic agents such as α-VEGF have 
been shown to prolong the survival of cancer patients.1,81
While SIRT1 clearly plays a critical role in development, ageing 
and protection against cancer development, several tumors exhibit 
enhanced expression levels of SIRT1 and appear to be dependent 
Figure 1. Signaling networks of SIRT1 involved in the maintenance of vas-
cular homeostasis. In endothelial cells SIRT1 modulates the transcriptional 
activity of Foxo1 and p53 and activates the enzymatic activity of the endo-
thelial nitric oxide synthase (eNOS). SIRT1 regulates cholesterol homeostasis 
by deacetylating the nuclear factor LXR in hepatocytes. By repressing the 
expression of the phosphatase PTP1B at the chromatin level, SIRT1 improves 

















SIRT1 and endothelial homeostasis
www.landesbioscience.com Cell Cycle 2121
on SIRT1 for proliferation and survival.82 Therefore, SIRT1-specific 
inhibitors may be useful and might evolve as additional chemothera-
peutic agents for tumors that depend on SIRT1 activity. Current 
strategies for anti-angiogenic therapy target early steps in the signal 
transduction cascade such as ligands or their cognate receptors.1,81,83 
Given the multitude of downstream factors targeted by SIRT1 
for deacetylation, SIRT1 might act as a nexus of several pathways 
common to the growth and vascularization of tumors and might, 
thus, represent alternative approach for blocking tumor progression.
While these considerations imply that strategies to modulate 
the activity of SIRT1 might serve as a potential therapy for age-
associated cardiovascular diseases or cancer, the rather ubiquitous 
expression and broad effects of SIRT1 might also pose significant 
hurdles with regard to specificity and side-effects.
Outlook
In summary, the findings of the recent studies point to SIRT1 as a 
novel regulator of vascular endothelial homeostasis, which plays a key 
role in the maintenance of vessel function. However, many questions 
remain to be answered. For instance, is SIRT1 active in pathologic 
vessels in growing tumors or other vascular-related diseases? Is SIRT1 
activity recruited by specific pathways such as VEGF/VEGFR2 
signaling to mediate its cellular responses? Likewise, it will be inter-
esting to investigate, how SIRT1 activity and expression is controlled 
in several physiologic and pathologic programs. Given the fact that 
most work so far focused on the biological actions of the closest Sir2 
homologue, SIRT1, in the vascular system, further studies will be 
required to address the functions of the other sirtuin family members 
in the vasculature and to link their mode of action with specific 
vascular programs.
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